Study Evaluating Ibuprofen 600 mg Extended Release (ER) For Dental Pain

NCT00913627 | Completed Phase 2 Results

• 2 other identifiers: AK-09-07B4371001
• Study Type: interventional
• Target: 196
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to assess the efficacy and safety of a single dose of an ibuprofen 600 mg extended release formulation in post-operative dental pain. There is concern that the manufacturing process may affect the performance characteristics of the selected prototype. Therefore, two formulations of this prototype manufactured by two different processes, \[roller compaction\] and \[wet granulation\] will be included in this study. The preferred prototype manufactured by two different methods will be compared to placebo and each other. This study will also characterize the pharmacokinetic/pharmacodynamic relationship with these formulations.

Conditions

Pain

Keywords

Extended-release; ibuprofen

Outcome Measures

Primary Outcomes (2)

• Time-weighted Sum of Pain Intensity Difference Score From 0 to 12 Hours (SPID 0-12)

  Pain intensity difference (PID) score based on 4-point categorical pain intensity rating scale. Participants asked, "How much pain do you have at this time?" Range of scale: None (0), Mild (1), Moderate (2), Severe (3). SPID derived by adding the time-weighted sums of PID scores over the time interval. Scores could range from -12 to 36 where higher positive values indicated improvement (decrease in pain intensity).

  Baseline (0 hour) to 12 hours post dose

• Time-weighted Sum of Pain Intensity Difference Score From 8 to 12 Hours (SPID 8-12)

  PID score based on 4-point categorical pain intensity rating scale. Participants asked, "How much pain do you have at this time?" Range of scale: None (0), Mild (1), Moderate (2), Severe (3). SPID score derived by adding the time-weighted sums of PID scores over the time interval. Scores could range from -4 to 12 where higher positive values indicated improvement (decrease in pain intensity).

  8 to 12 hours post dose

Secondary Outcomes (15)

• Time to First Perceptible Pain Relief

  Baseline to 6 hours

• Time to Treatment Failure

  Baseline to 24 hours

• Percentage of Participants With Treatment Failure

  8, 9, 10, 11, and 12 hours

• Time-weighted Sum of Pain Intensity Difference From 0 to 4 Hours (SPID 0-4) and 4 to 8 Hours (SPID 4-8)

  0 to 4 hours and 4 to 8 hours

• Time-weighted Sum of Pain Relief and Pain Intensity Difference Scores (SPRID)

  0 to 4 hours, 4 to 8 hours, 8 to 12 hours, and 0 to 12 hours

Study Arms (4)

1

EXPERIMENTAL

1 x 600 mg ibuprofen IR/ER-roller compaction caplet

Drug: ibuprofen

2

EXPERIMENTAL

1 x 600 mg ibuprofen IR/ER-Wet granulation caplet

Drug: ibuprofen

3

ACTIVE COMPARATOR

1x 220 mg naproxen sodium (Aleve caplet)

Drug: naproxen

4

PLACEBO COMPARATOR

1 x placebo caplet

Drug: Placebo

Interventions

ibuprofen DRUG

1

naproxen DRUG

3

Placebo DRUG

4

Eligibility Criteria

• Age: 16 Years - 40 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Males and females 16 to 40 years of age.
• Outpatients who undergo surgical extraction of 1-2 third molars, one of which must be a partial or full bony mandibular impaction and have moderate to severe post-operative pain (confirmed by a VAS score of at least 50 mm on a 100 mm VAS) following surgical extraction;
• Use of only the following preoperative medication(s)/anesthetic(s): short-acting local anesthetic (mepivacaine or lidocaine) with or without vasoconstrictor, nitrous oxide, and/or midazolam;
• Reliable, cooperative, and of adequate intelligence to record the requested information on the analgesic questionnaire form;
• Examined by the attending dentist or physician and medically cleared to participate in the study;
• In general good health and have no contraindications to the study medication.

You may not qualify if:

• Pregnancy, as verified by a urine-based pregnancy test, or breast feeding;
• Presence of a serious medical condition (e.g., poorly controlled hypertension, poorly controlled diabetes, significantly impaired cardiac, renal or hepatic function, poorly-controlled hyper- or hypothyroidism);
• Use of a prescription or nonprescription drug with which the administration of ibuprofen or any other NSAID is contraindicated;
• Use of a bisphosphonate (e.g., risedronate \[Actonel\], alendronate \[Fosamax\], or ibandronate \[Boniva\]) in the past 5-years;
• Acute localized dentalveolar infection at the time of surgery that could confound the post-surgical evaluation;
• Females who are of child-bearing potential, or post-menopausal for less than 2 years and not using a medically approved method of contraception (i.e., oral, transdermal, or implanted contraceptives, intrauterine device, diaphragm, condom, abstinence, or surgical sterility), or females who test positive on a urine-based pregnancy test;
• Presence or history (within 2 years of enrollment) of bleeding disorder(s) or peptic ulcer disease;
• History of alcoholism (i.e., on average, consumes 3 or more alcoholic drinks per day) or substance abuse within the last year, or is currently abusing alcohol or other mood-altering drugs (e.g., cannabis). Patients who are taking CNS or other psychotropic drugs (including St. John's Wort, or any other nutritional supplement known to have psychotropic effects) may be enrolled if they have been on stable doses of medication for at least 2 months, will maintain this dose throughout the study, and their condition is judged by the Principal Investigator to be well-controlled;
• Habituation to analgesic drugs (i.e., routine use of oral analgesics 5 or more times per week)
• History of allergic reaction (e.g., asthma, rhinitis, swelling, shock, or hives) to ibuprofen, naproxen, aspirin, or to any other NSAID; or to codeine, hydrocodone, or acetaminophen, or to their combinations;
• Prior use of any type of analgesic or NSAID five half-lives of that drug or less before taking the first dose of study medication, except for pre-anesthetic medication and anesthesia for the procedure;
• Ingestion of any caffeine-containing beverages, chocolate, or alcohol 4 hours or less before taking the first dose of study medication;
• The subject has taken an investigational product or participated in an investigational trial within 30 days of study enrollment;
• The subject has previously participated in this study;
• The subject is a member of the study site staff directly involved with the study, an employee of the Sponsor, or a relative of study site personnel directly involved with the study.

Sponsors & Collaborators

• Pfizer: lead

Study Sites (1)

Jean Brown Research Center

Salt Lake City, Utah, 84124, United States

Location

Related Links

• To obtain contact information for a study center near you, click here.

MeSH Terms

Conditions

Pain

Interventions

Ibuprofen; Naproxen

Condition Hierarchy (Ancestors)

Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Phenylpropionates; Acids, Carbocyclic; Carboxylic Acids; Organic Chemicals; Naphthaleneacetic Acids; Naphthalenes; Polycyclic Aromatic Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Polycyclic Compounds

Results Point of Contact

• Title: Pfizer ClinicalTrials.gov Call Center
• Organization: Pfizer, Inc.

ClinicalTrials.gov_Inquiries@pfizer.com

1-800-718-1021

Study Officials

• Pfizer CT.gov Call Center

  Pfizer

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 29, 2009
• First Posted: June 4, 2009
• Study Start: May 7, 2009
• Primary Completion: August 1, 2009
• Study Completion: August 5, 2009
• Last Updated: March 22, 2018
• Results First Posted: March 22, 2018

Record last verified: 2018-02

Locations

US (1)